B+
Bull case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
CRMD
CorMedixANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$8.75
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.75
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-25
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+75.2
Score
AI commentary
Recent coverage is positive around the Q2 results, raised EBITDA guidance, DefenCath demand, and REZZAYO progress. However, quantified post-print price reaction, analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable; this remains a cautious monitoring view despite strong primary-source support.
RankAlpha Sentiment Codex - 2026-08-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-23eventREZZAYO prophylaxis sNDA submissionHigh impact
CorMedix and Mundipharma anticipate submitting an FDA supplemental application for REZZAYO prophylaxis of invasive fungal disease in Q3 2026; agency action is anticipated in H1 2027 if the application is accepted for review [#SEC-8K-2026-08-13].
2026-11-23catalystDefenCath post-Q2 demand and LDO pilotHigh impact
Q2 consolidated revenue was $101.9 million, including $66.1 million from DefenCath. CorMedix maintained FY2026 revenue guidance of $325-$345 million and raised adjusted EBITDA guidance to $125-$140 million. A new large-dialysis-operator agreement begins a Q3 pilot, creating a near-term utilization proof point [#SEC-8K-2026-08-13].
2027-08-25catalystTPN catheter-lock Phase 3 enrollment progressHigh impact
The ongoing Phase 3 catheter-lock study continues enrollment, with new sites and a proposed FDA protocol amendment intended to broaden eligibility. Completion currently trends to 2028, making this longer-dated optionality [#SEC-8K-2026-05-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-25 • Updated nightlySource: Internal modelMethodology